WEKO3
アイテム
{"_buckets": {"deposit": "3a7634fc-d058-4455-b561-61e9dce0226d"}, "_deposit": {"id": "26876", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "26876"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00026876", "sets": ["501"]}, "author_link": ["88042", "88043", "88044", "88045", "88046", "88047", "88048", "88049", "88050", "88051"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "319", "bibliographicPageStart": "312", "bibliographicVolumeNumber": "40", "bibliographic_titles": [{"bibliographic_title": "International Journal of Laboratory Hematology", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Introduction: Antithrombin resistance (ATR) is a novel thrombotic risk in abnormal prothrombins. A manual ATR assay using Oxyuranus scutellatus (Ox) venom as a prothrombin activator was established for detecting antithrombin‐resistant prothrombin. However, this assay was limited because of Ox snake venom availability and its throughput capacity. Here, we have improved the ATR assay using bovine factors Xa and Va (FXa/Va) as prothrombin activators and have optimised assay conditions for an automated instrument (ACL TOP 500). Methods: Diluted plasma was incubated with a prothrombin activator mix (phospholipids, CaCl2, and bovine FXa/Va), followed by inactivation with antithrombin for 10, 20 and 30 minutes. We added a chromogenic substrate S‐2238, and assessed changes in absorbance/min at 405 nm. We also adapted assay conditions for ACL TOP 500. Results: Optimum conditions for FXa/Va treatment were 6.25% phospholipids, 5 mM CaCL2, 0.01 μg/mL FXa and 0.1 μg/mL FVa. ATR assay kinetics with the FXa/Va activator was comparable with that with the Ox activator in heterozygous reconstituted plasma with the recombinant wild‐type or antithrombin‐resistant prothrombin. Using ACL TOP 500, optimum conditions for the FXa/Va treatment were 10.0% phospholipids, 5 mM CaCl2, 0.02 μg/mL FXa and 0.2 μg/mL FVa. The automated ATR assay with the FXa/Va activator demonstrated good detectability for antithrombin‐resistant prothrombin in plasma from a heterozygous carrier with prothrombin Yukuhashi or Belgrade. Conclusion: We optimised the ATR assay with the FXa/Va activator and adapted the assay for ACL TOP 500; the assay showed the ability to clearly detect antithrombin‐resistant prothrombin in manual and automated procedures.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "ファイル公開:2019-06-01", "subitem_description_language": "ja", "subitem_description_type": "Other"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1111/ijlh.12786", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "This is the peer reviewed version of the following article: [Tamura S, Suga Y, Tanamura M, et al. Optimisation of antithrombin resistance assay as a practical clinical laboratory test: Development of prothrombin activator using factors Xa/Va and automation of assay. Int J Lab Hem. 2018;40:312–319. https://doi.org/10.1111/ijlh.12786], which has been published in final form at [https://doi.org/10.1111/ijlh.12786]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_61": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "1751-5521", "subitem_source_identifier_type": "PISSN"}]}, "item_10_source_id_62": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "1751-553X", "subitem_source_identifier_type": "EISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Tamura, S.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88042", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suga, Y.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88043", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanamura, M.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88044", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murata-Kawakami, M.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88045", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takagi, Y.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88046", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hottori, Y.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88047", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kakihara, M.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88048", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, S.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88049", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takagi, A.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88050", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kojima, T.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88051", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-06-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Tamuraet_al_Int_J_Lab_Hematol2018.pdf", "filesize": [{"value": "448.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 448300.0, "url": {"label": "Tamuraet_al_Int_J_Lab_Hematol2018", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/26876/files/Tamuraet_al_Int_J_Lab_Hematol2018.pdf"}, "version_id": "dcfd7759-e833-4ab8-b48b-7b1469b404ce"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "ACL TOP 500", "subitem_subject_scheme": "Other"}, {"subitem_subject": "antithrombin resistance", "subitem_subject_scheme": "Other"}, {"subitem_subject": "FXa/Va activator", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Ox venom", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prothrombin", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Optimisation of antithrombin resistance assay as a practical clinical laboratory test : Development of prothrombin activator using factors Xa/Va and automation of assay", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Optimisation of antithrombin resistance assay as a practical clinical laboratory test : Development of prothrombin activator using factors Xa/Va and automation of assay", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/00029079", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2018-11-28"}, "publish_date": "2018-11-28", "publish_status": "0", "recid": "26876", "relation": {}, "relation_version_is_last": true, "title": ["Optimisation of antithrombin resistance assay as a practical clinical laboratory test : Development of prothrombin activator using factors Xa/Va and automation of assay"], "weko_shared_id": -1}
Optimisation of antithrombin resistance assay as a practical clinical laboratory test : Development of prothrombin activator using factors Xa/Va and automation of assay
http://hdl.handle.net/2237/00029079
http://hdl.handle.net/2237/0002907971c90639-4671-48ed-a422-bc7e6fcf7f6e
名前 / ファイル | ライセンス | アクション |
---|---|---|
Tamuraet_al_Int_J_Lab_Hematol2018 (448.3 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-11-28 | |||||
タイトル | ||||||
タイトル | Optimisation of antithrombin resistance assay as a practical clinical laboratory test : Development of prothrombin activator using factors Xa/Va and automation of assay | |||||
言語 | en | |||||
著者 |
Tamura, S.
× Tamura, S.× Suga, Y.× Tanamura, M.× Murata-Kawakami, M.× Takagi, Y.× Hottori, Y.× Kakihara, M.× Suzuki, S.× Takagi, A.× Kojima, T. |
|||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
権利 | ||||||
言語 | en | |||||
権利情報 | This is the peer reviewed version of the following article: [Tamura S, Suga Y, Tanamura M, et al. Optimisation of antithrombin resistance assay as a practical clinical laboratory test: Development of prothrombin activator using factors Xa/Va and automation of assay. Int J Lab Hem. 2018;40:312–319. https://doi.org/10.1111/ijlh.12786], which has been published in final form at [https://doi.org/10.1111/ijlh.12786]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | ACL TOP 500 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | antithrombin resistance | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | FXa/Va activator | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Ox venom | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | prothrombin | |||||
抄録 | ||||||
内容記述 | Introduction: Antithrombin resistance (ATR) is a novel thrombotic risk in abnormal prothrombins. A manual ATR assay using Oxyuranus scutellatus (Ox) venom as a prothrombin activator was established for detecting antithrombin‐resistant prothrombin. However, this assay was limited because of Ox snake venom availability and its throughput capacity. Here, we have improved the ATR assay using bovine factors Xa and Va (FXa/Va) as prothrombin activators and have optimised assay conditions for an automated instrument (ACL TOP 500). Methods: Diluted plasma was incubated with a prothrombin activator mix (phospholipids, CaCl2, and bovine FXa/Va), followed by inactivation with antithrombin for 10, 20 and 30 minutes. We added a chromogenic substrate S‐2238, and assessed changes in absorbance/min at 405 nm. We also adapted assay conditions for ACL TOP 500. Results: Optimum conditions for FXa/Va treatment were 6.25% phospholipids, 5 mM CaCL2, 0.01 μg/mL FXa and 0.1 μg/mL FVa. ATR assay kinetics with the FXa/Va activator was comparable with that with the Ox activator in heterozygous reconstituted plasma with the recombinant wild‐type or antithrombin‐resistant prothrombin. Using ACL TOP 500, optimum conditions for the FXa/Va treatment were 10.0% phospholipids, 5 mM CaCl2, 0.02 μg/mL FXa and 0.2 μg/mL FVa. The automated ATR assay with the FXa/Va activator demonstrated good detectability for antithrombin‐resistant prothrombin in plasma from a heterozygous carrier with prothrombin Yukuhashi or Belgrade. Conclusion: We optimised the ATR assay with the FXa/Va activator and adapted the assay for ACL TOP 500; the assay showed the ability to clearly detect antithrombin‐resistant prothrombin in manual and automated procedures. | |||||
言語 | en | |||||
内容記述タイプ | Abstract | |||||
内容記述 | ||||||
内容記述 | ファイル公開:2019-06-01 | |||||
言語 | ja | |||||
内容記述タイプ | Other | |||||
出版者 | ||||||
言語 | en | |||||
出版者 | Wiley | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプresource | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1111/ijlh.12786 | |||||
ISSN(print) | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 1751-5521 | |||||
ISSN(Online) | ||||||
収録物識別子タイプ | EISSN | |||||
収録物識別子 | 1751-553X | |||||
書誌情報 |
en : International Journal of Laboratory Hematology 巻 40, 号 3, p. 312-319, 発行日 2018-06 |
|||||
著者版フラグ | ||||||
値 | author |